Biotech: Page 72
-
Permission granted by Eikon Therapeutics
Roger Perlmutter, former Merck research chief, resurfaces to lead a small biotech
Months after leaving his post as Merck's top scientist, Perlmutter has become CEO of Eikon Therapeutics, which plans to use Nobel Prize-winning microscope technology to discover new drugs.
By Ben Fidler • May 5, 2021 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49535193876/in/album-72157713108522106/.
Adagio, flush with cash, launches large study of next-gen COVID-19 antibody
The privately held biotech believes its drug might treat or prevent infections from existing variants and future coronavirus strains, which could make it a competitor to marketed therapies from Regeneron and Eli Lilly.
By Kristin Jensen • May 5, 2021 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Permission granted by Esker Therapeutics
Esker, a new biotech startup, launches with plans to make targeted immune drugs
Led by a former MyoKardia executive, Esker Therapeutics is developing a drug that could eventually compete with one of Bristol Myers Squibb's most closely watched candidates.
By Jonathan Gardner • May 5, 2021 -
Sage braces for make-or-break depression data
The biotech's latest earnings call focused less on revenue and more on an experimental drug for depression that's close to having important study results.
By Jacob Bell • May 4, 2021 -
Courtesy of Sarepta
Sarepta's second-gen Duchenne drug shows signs of topping its first
An experimental Duchenne drug developed with a newer technology may be more potent than Sarepta's marketed treatment Exondys 51. But early data also brought new safety concerns.
By Jonathan Gardner • May 3, 2021 -
Roivant valued at $7B in blank-check merger, bucking SPAC slowdown
Vivek Ramaswamy's unusual biotech holding company will go public through a deal with Montes Archimedes Acquisition Corp. that nets Roivant $611 million.
By Ben Fidler • May 3, 2021 -
Jacob Bell/BioPharma Dive
Avrobio changes course after FDA closes path for speedy gene therapy approval
The FDA recently converted its clearance for a standard Fabry treatment to a full approval, complicating Avrobio's plans to seek an accelerated OK for its rare disease therapy.
By Ned Pagliarulo • May 3, 2021 -
A serious side effect puts a biotech's eye gene therapy in limbo
Adverum Biotechnologies has unmasked a Phase 2 study in which a trial participant suffered severe inflammation and vision loss — a finding that could threaten the program’s future in multiple eye diseases.
By Ben Fidler • April 29, 2021 -
Maddie Meyer via Getty Images
Moderna plans to triple coronavirus vaccine production next year
The biotech aims to double capacity at plants in Switzerland and Spain, and by 50% at U.S. sites. The total number, however, will depend on the mix of primary and booster doses.
By Jonathan Gardner • April 29, 2021 -
Wall Street fears Amgen's tough first quarter is just the start
Product sales fell by 5% in the first quarter, keeping the pressure high for Amgen to deliver on expectations for its KRAS cancer drug Lumakras.
By Jacob Bell • April 28, 2021 -
Permission granted by Biogen
Under pressure, Biogen will allow some patients early access to experimental ALS drug
Biogen plans to start a compassionate use program in July that would let a small group of patients with rapidly progressing disease access its drug.
By Jacob Bell • April 27, 2021 -
Vertex moves pain drug into mid-stage testing
VX-548 is Vertex's latest attempt to show that blocking a certain sodium channel can offer a new, non-addictive way to treat pain.
By Jacob Bell • April 26, 2021 -
Coronavirus vaccine makers Oxford, Novavax follow up with a promising malaria shot
A vaccine co-developed by the U.K. academic center and the Maryland biotech could be the first to meet the WHO's efficacy target for a malaria vaccine.
By Ben Fidler • April 23, 2021 -
Permission granted by Biogen
As review of its Alzheimer's drug wraps up, Biogen prepares for an uncertain launch
On an earnings call Thursday, executives shed more light on how they intend to address some of the challenges that would come with selling a controversial drug like aducanumab.
By Jacob Bell • April 22, 2021 -
With money pouring into biotech, Versant raises another $950M
Versant's announcement comes as biotechs continue to rake in record levels of cash, supporting a wave of new drug company startups.
By Jacob Bell • April 21, 2021 -
The next 2 months in biotech and pharma will be busy. Here's what to watch.
New developments could come soon for two coronavirus vaccines while, a bit further off, the fate of Biogen's Alzheimer's drug hangs in the balance. Important data are expected, too, for Vertex and Sarepta.
By Ben Fidler , Ned Pagliarulo , Jacob Bell • April 20, 2021 -
Getty / Edited by BioPharma Dive
Bluebird to withdraw gene therapy from Germany after dispute over price
The biotech will cut staff, primarily in Europe, after negotiations with German health authorities resulted in a price lower than Bluebird had sought.
By Ned Pagliarulo • April 20, 2021 -
Vertex bets another $900M on CRISPR treatment for blood diseases
Vertex and CRISPR Therapeutics are tweaking their partnership so that the larger biotech will cover 60% of the costs — and receive 60% of the future profits — related to a gene editing therapy for sickle cell disease and beta thalassemia.
By Jacob Bell • April 20, 2021 -
Positive data in hand, TG Therapeutics readies MS drug for FDA review
If approved, TG's drug would join Roche's fast-selling Ocrevus and Novartis' newer entrant Kesimpta as one of a newer class of multiple sclerosis therapies.
By Jonathan Gardner • April 19, 2021 -
Permission granted by Adagio Therapeutics
A startup raises $336M to make a better antibody drug for COVID-19
Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests.
By Ben Fidler • April 19, 2021 -
Permission granted by Relay Therapeutics
Relay buys AI startup to aid unorthodox drug discovery quest
The $85 million acquisition is an unusual and early step for a company like Relay, which went public last July and only just began clinical testing of its lead drugs last year.
By Ned Pagliarulo • April 16, 2021 -
Jacob Bell/BioPharma Dive
FDA faces backlash after seeking more data on an experimental ALS therapy
The ALS Association demanded the FDA "move with the urgency" other agencies have in reviewing a drug from Amylyx Pharmaceuticals.
By Jacob Bell • April 14, 2021 -
Maddie Meyer via Getty Images
Moderna watches for 'waning immunity' as new data show durable vaccine protection
Updated study results show Moderna's coronavirus vaccine was strongly protective against COVID-19 through six months. But executives outlined contingency plans in case those effects fade.
By Ben Fidler • April 14, 2021 -
Permission granted by Gilead Sciences
Gilead stops Veklury study, citing enrollment challenges, changing treatment
The company said a multi-day infusion treatment that must be administered in healthcare settings no longer addresses an unmet need of non-hospitalized COVID-19 patients.
By Jacob Bell • April 13, 2021 -
Lilly, Arch join Deerfield in backing new gene therapy biotech Jaguar
Just two months after launching, Jaguar Gene Therapy has raised another $139 million for a preclinical pipeline aimed at gene-linked autism and diabetes.
By Ned Pagliarulo • Updated April 13, 2021
Previous
